Fundamento racional para el tratamiento precoz de la esclerosis multiple

Translated title of the contribution: Rational for an early treatment of multiple sclerosis

Research output: Contribution to journalArticlepeer-review


Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) of unknown etiology. Its pathological hallmark is the presence within the CNS of inflammatory infiltrates containing few autoreactive T cells and a multitude of pathogenic nonspecific lymphocytes. Based on that, various non-specific immunosuppressive agents have been tested with marginal benefits on the natural evolution of the disease and frequent short- and long-term adverse effects. Moreover, due to their unfavourable profile, these therapies have been usually limited to patients with progressive courses or high clinical activity. The recent approval of IFNβ and Copolymer 1, as therapies able to modify the disease course in relapsing-remitting and secondary progressive, as well as the available immunopathological and clinical data suggesting that the early treatment of MS with safe profile immunomodulatory drugs could be advantageous compared to late treatments, supports the 'putative' relevance of these new drugs in the early treatment of MS patients. However we must wait for the results of ongoing clinical trials to define if such an early treatment has substantial advantages compared to late treatment.

Translated title of the contributionRational for an early treatment of multiple sclerosis
Original languageSpanish
Pages (from-to)1265-1268
Number of pages4
JournalRevista de Neurologia
Issue number12
Publication statusPublished - Jun 16 2000


  • Copolymer 1
  • Early treatment
  • IFNβ
  • Immunomodulatory drugs
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Rational for an early treatment of multiple sclerosis'. Together they form a unique fingerprint.

Cite this